PRXV - ETF AI Analysis

Top Page

Praxis Impact Large Cap Value ETF (PRXV)

Rating:72Outperform

Price Target:―

PRXV, the Praxis Impact Large Cap Value ETF, earns a solid overall rating thanks to strong, diversified holdings like Micron, Johnson & Johnson, Walmart, and Cisco, which all show healthy financial performance, positive earnings calls, and generally supportive technical trends. These leaders are partly offset by weaker spots such as Home Depot and AbbVie, where bearish technical signals, leverage, and valuation concerns weigh on their outlook. A key risk for the ETF is exposure to companies with high debt and less attractive valuations, which could limit upside if market conditions worsen.

Positive Factors

Broad Sector Diversification

The fund spreads its investments across many sectors, which can help reduce the impact if any one industry struggles.

Mix of Defensive and Growth-Oriented Holdings

Top positions include steady consumer and health care names alongside faster-growing technology stocks, offering a balance of stability and growth potential.

Solid Recent Performance Trend

The ETF has shown positive returns over the past month, three months, and year to date, indicating recent momentum in its strategy.

Negative Factors

Heavy U.S. Market Concentration

With almost all assets in U.S. stocks, the fund offers little geographic diversification and is highly tied to the U.S. market’s fortunes.

Notable Weakness in Some Top Financial Holdings

Several large financial stocks in the top holdings have been weak so far this year, which can drag on overall returns if the sector stays under pressure.

Moderate Expense Ratio

The fund’s fee is not especially low for a large-cap ETF, which slightly reduces the net return investors keep over time.

PRXV vs. SPDR S&P 500 ETF (SPY)

AUM66.74M

RegionNorth America

Expense Ratio0.36%

Beta0.63

IssuerPraxis

Inception DateApr 08, 2025

Dividend Yield1.06%

Asset ClassEquity

Index TrackedNo Underlying Index

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume6,881

30 Day Avg. Volume9,007

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

35.64

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering274

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

PRXV Summary

The Praxis Impact Large Cap Value ETF (PRXV) invests mainly in large, established U.S. companies that appear undervalued and also meet certain environmental, social, and governance (ESG) standards. It does not track a specific index, but focuses on value stocks across many sectors like financials, health care, and technology. Well-known holdings include JPMorgan Chase and Johnson & Johnson. Someone might invest in this ETF to seek long-term growth while aligning their money with their values and getting broad diversification. A key risk is that value stocks and the overall stock market can go up and down, sometimes sharply.

How much will it cost me?The Praxis Impact Large Cap Value ETF (PRXV) has an expense ratio of 0.36%, which means you’ll pay $3.60 per year for every $1,000 invested. This is slightly higher than average for ETFs because it is actively managed and focuses on socially responsible investing, which requires more research and oversight. It’s a good option if you value ethical considerations alongside financial returns.

What would affect this ETF?The PRXV ETF, with its focus on large-cap value stocks and ESG criteria, could benefit from increased investor interest in socially responsible investing and strong performance in sectors like financials and healthcare. However, it may face challenges if economic conditions weaken, particularly in North America, or if regulatory changes impact ESG-focused investments. Sector-specific risks, such as volatility in energy or technology, could also influence its future performance.

PRXV Top 10 Holdings

PRXV leans heavily on U.S. financials and health care, with JPMorgan and Bank of America acting as big anchors—recently more of a drag than a lift as their shares have been lagging. On the brighter side, Micron has been the fund’s spark plug, riding strong momentum tied to AI and memory demand. Steady consumer giants like Walmart and Coca-Cola help smooth the ride, while Johnson & Johnson adds a solid, rising health care presence. Overall, it’s a U.S.-centric value portfolio with a cautious tilt toward stability plus a dash of tech-driven upside.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
JPM	JPMorgan Chase	3.61%	$2.40M	$828.34B	10.57%	72 Outperform
JNJ	Johnson & Johnson	2.62%	$1.74M	$586.40B	55.16%	78 Outperform
WMT	Walmart	2.39%	$1.59M	$1.03T	21.75%	78 Outperform
PG	Procter & Gamble	2.06%	$1.37M	$370.79B	-5.78%	69 Neutral
MU	Micron	1.97%	$1.31M	$449.96B	303.36%	79 Outperform
ABBV	AbbVie	1.77%	$1.18M	$411.55B	15.90%	66 Neutral
HD	Home Depot	1.65%	$1.10M	$381.32B	-3.01%	66 Neutral
BAC	Bank of America	1.53%	$1.02M	$380.39B	15.97%	72 Outperform
KO	Coca-Cola	1.51%	$1.00M	$342.24B	13.44%	75 Outperform
MRK	Merck & Company	1.41%	$937.30K	$301.74B	42.13%	80 Outperform

PRXV Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

31.17

Positive

100DMA

30.33

Positive

200DMA

29.21

Positive

Market Momentum

MACD

0.43

Negative

RSI

65.38

Neutral

STOCH

64.12

Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PRXV, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 32.00, equal to the 50-day MA of 31.17, and equal to the 200-day MA of 29.21, indicating a bullish trend. The MACD of 0.43 indicates Negative momentum. The RSI at 65.38 is Neutral, neither overbought nor oversold. The STOCH value of 64.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRXV.

PRXV Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
PRXV	―	―	$66.74M	0.36%	―
MAVF	―	―	$86.43M	0.75%	―
CGVV	―	―	$83.16M	0.33%	―
ITAN	―	―	$72.49M	0.50%	―
FLCV	―	―	$70.91M	0.32%	―
DHLX	―	―	$67.96M	0.55%	―

Performance Comparison

PRXV

Praxis Impact Large Cap Value ETF

32.60

6.98

27.24%

MAVF

Matrix Advisors Value ETF

―

CGVV

Capital Group U.S. Large Value ETF

―

ITAN

Sparkline Intangible Value ETF

―

FLCV

Federated Hermes MDT Large Cap Value ETF

―

DHLX

Diamond Hill Large Cap Concentrated ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents